February 22, 2026 Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
January 30, 2026 KIST: New Membrane Advances Green Hydrogen Production via Low-Alkalinity Electrolysis